NovartisNovartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2009, the Group's continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 102,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit

Novartis RSS Channel

Title Filter      Display #  
# Article Title
1 FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz
2 Novartis announces completion of transactions with GSK
3 Novartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myeloma
4 Novartis Pharmaceuticals announces a joint investment company with Qualcomm
5 Novartis collaborates with Intellia Therapeutics and Caribou Biosciences
6 Novartis Foundation symposium showcases sustainable healthcare interventions
7 New data on the global economic impact and burden of preventable blindness and vision impairment
8 Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb's novel immunotherapy in combination treatments for NSCLC
9 Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
10 Novartis provides drug candidate compounds to TB Alliance
11 Novartis maintained strong innovation momentum in second quarter
12 Novartis to license Google "smart lens" technology
13 Novartis reinforces its leadership in research with new global guidelines for Investigator Initiated Trials (IITs)
14 Novartis launches 7-Day Challenge to 'Live Like You' enabling people with MS to better understand their lives with MS
15 More than 19,000 Novartis associates worldwide volunteer for local causes on Community Partnership Day
16 Novartis delivered solid sales and profit growth in the first quarter of 2014
17 Novartis announces portfolio transformation
18 Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia
19 Novartis announces US FDA approval of Xolair® for chronic idiopathic urticaria
20 Novartis extends leadership in clinical trial data transparency
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]